Gold bars to be exempt from tariffs, White House clarifies
Brian Kenneth Roberts, Chief Medical (TASE:BLWV) Officer of Rezolute , Inc. (NASDAQ:RZLT), a $370 million market cap biotech company, acquired 2,500 shares of common stock on June 25, 2025. According to InvestingPro data, analysts have set price targets between $9-$15, suggesting significant upside potential from current levels. The purchases were executed at prices ranging from $4.37 to $4.38, resulting in a total transaction value of $10939.
Following the transaction, Roberts directly owns 15500 shares of Rezolute, Inc. common stock. In addition, he indirectly owns 1,376 shares held by a minor child and directly holds another 157,352 shares.
In other recent news, Rezolute, Inc. announced a $90 million stock and warrant offering, involving over 20 million shares of common stock and nearly 7 million pre-funded warrants. The proceeds are intended for research and development, general corporate expenses, and working capital needs. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Rezolute’s drug candidate, ersodetug, for treating hypoglycemia caused by tumor hyperinsulinism. This recognition aims to expedite the development and review process due to the drug’s potential significant improvement over existing treatments.
In another development, the Independent (LON:IOG) Data Monitoring Committee recommended that the Phase 3 sunRIZE trial continue without changes, reinforcing confidence in the trial’s design and assumptions. BTIG analyst Julian Harrison reaffirmed a Buy rating on Rezolute, maintaining a $15 price target. The analyst highlighted the successful enrollment for the sunRIZE trial and expressed optimism about the drug’s prospects. Additionally, Rezolute appointed Erik Harris to its Board of Directors, bringing extensive biopharmaceutical industry experience to the company. Harris’s expertise is expected to aid in the clinical advancement and potential commercialization of Rezolute’s lead programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.